Nascent Biotech Announces Key Personnel Additions in Preparation for Coming Phase One Clinical Studies

October 7, 2020 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / October 7, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech" or the "Company") announces today that the Company is in the process of making significant additions to its core team in order to prepare for the initiation of key Phase One clinical trials to study the safety and efficacy of the Company's flagship drug, Pritumumab (PTB), a monoclonal antibody, for the treatment of Brain...

Read more

GB Sciences Files Provisional Patent Application for the Treatment of Chronic Inflammation Utilizing Its Novel Cannabinoid Containing Complex Mixtures (CCCM)

October 6, 2020 9:00 AM

LAS VEGAS, NV / ACCESSWIRE / October 6, 2020 / ​GB Sciences, Inc. (OTCQB:GBLX), has filed a provisional patent application, assigned to GBS Global Biopharma (GBS), Inc., for the use of its new proprietary cannabinoid containing complex mixtures (CCCM™) for the treatment of chronic inflammation. Chronic inflammation represents a serious global health and economic burden with over $130 billion spent annually.  Based on data from a...

Read more

electroCore to Participate in the MicroCap Rodeo: The Best Ideas Bowl

October 6, 2020 8:00 AM

BASKING RIDGE, NJ / ACCESSWIRE / October 6, 2020 / electroCore, Inc. (Nasdaq:ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, chief executive officer, will provide a corporate update at the MicroCap Rodeo Best Ideas Bowl, which is being held virtually October 13-16, 2020. Event details: Date: Tuesday, October 13 Time: 1:30pm ET Audio from the event will be webcast live and available here...

Read more

Hemogenyx Pharmaceuticals PLC Announces SAFE-HEMO-CAR-T Effective against AML in vitro

October 6, 2020 2:00 AM

LONDON, UK / ACCESSWIRE / October 6, 2020 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce the following update on its activities. As previously announced, Hemogenyx Pharmaceuticals' CDX bi-specific antibody has the potential to treat Acute Myeloid Leukemia ("AML") directly as well as to provide a benign conditioning regimen...

Read more

Molecular Partners Demonstrates Reduction of Mortality and Potent Therapeutic Activity of Anti-COVID-19 DARPin(R) Candidates in Advanced COVID-19 Disease Model

October 6, 2020 1:00 AM

DARPin® Candidates Demonstrate 100% Survival in an Aggressive Viral Challenge Model Data Support Utility of Anti-COVID-19 DARPin® Candidates As Potent Therapeutics First-in-Human Clinical Trial Initiation of MP0420 Planned for November 2020 ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE /...

Read more

OMNICANNA to Launch its Industrial Hemp Real-Time Trading eCommerce Website, October 9, 2020, Featuring Disruptive Real-Time Negotiating Technology, Providing All Buyers and Sellers Powerful Tools to Navigate, Find, & Track Industrial Hemp Inventory

October 5, 2020 11:38 AM

RALEIGH, NC / ACCESSWIRE / October 5, 2020 / Omnicanna Health Solutions, Inc. (OTC PINK:ENDO), a U.S. Company specializing in hemp formulation-based health and wellness solutions, is pleased to announce it will release its Industrial Hemp Real-Time Negotiating eCommerce website, October 9, 2020. Featuring Advanced Disruptive Real-Time Negotiating Technology. Providing powerful online tools to All Buyers and Sellers of Industrial Hemp...

Read more

Wuhan General Group Appoints Willem Jonker as Chief Operating Officer

October 5, 2020 9:30 AM

CAPE TOWN, SA / ACCESSWIRE / October 5, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is delighted to share today the appointment of Mr. Willem Jonker, CA(SA), as Chief Operating Officer of the Cannabis Cultivation Project effective immediately. Willem is an experienced leader and a...

Read more

Qrons files U.S. National Phase of its Patent Application

October 5, 2020 9:00 AM

NEW YORK, NY / ACCESSWIRE / October 5, 2020 / Qrons Inc. (OTCQB:QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries (TBIs) and other nervous system pathologies, today announced that it has filed in the United States Patent and Trademark Office (USPTO), the US National Phase of its international (PCT) patent application, thereby initiating...

Read more

Havn Life Sciences Announces Appointments of Vic Neufeld as Chairman and Rick Brar as Vice Chairman of the Board of Directors, Respectively, and the Acceleration of Warrants

October 5, 2020 8:00 AM

VANCOUVER, BC / ACCESSWIRE / October 5, 2020 / Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the "Company" or "Havn Life") is pleased to announce that Mr. Vic Neufeld has been appointed as the Chairman of the Board of Directors of the Company (the "Board"). Mr. Neufeld brings a wealth of knowledge and experience in the Natural Health Food industry, having served as the Chief Executive Officer of Jamieson Laboratories...

Read more

Enzolytics, Inc. Announces New Board Member, Charles Cotropia, CEO of BioClonetics Immunotherapeutics, Inc. Harry Zhabilov CEO of Enzolytics to Join Board of BioClonetics

October 1, 2020 9:00 AM

PLANO, TX / ACCESSWIRE / October 1, 2020 / Enzolytics, Inc. (OTC PINK:ENZC) or (the "Company") today announced the addition of Charles Cotropia to the Company's Board of Directors. ENZC entered into a Letter of Intent (the "LOI") to merge with BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics"), a biotech company located in Dallas Texas, on September 15, 2020. In addition, the Company...

Read more

Nascent Biotech Continues to Reduce Liabilities by Over $2.0 Million Dollars

October 1, 2020 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / October 1, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) Announced today that It has continued to reduce its liabilities through stock conversion and payment of accounts payable and accrued liabilities. The reduction was achieved through the conversion of debt to equity and the reduction of liabilities, including its last convertible note. The convertible note's principal is now $11,250 down from $161,250, a...

Read more

ITOCO Completes Blockchain Smart Contract for Immutable Virus Test Result Verification System

October 1, 2020 7:00 AM

TORONTO, ON / ACCESSWIRE / October 1, 2020 / ITOCO INC. (OTC PINK:ITMC) has successfully completed and deployed the blockchain portion of its patent-pending Immutable Virus Test Result Verification System to the Ethereum Ropsten test network. This important first step in commercializing the patent-pending technology, acquired through its previously announced agreement with DATANet Software, and making it available to prospective clients...

Read more

Vitro Biopharma 3rd Quarter ended July 31st 2020 Financial Results of Operations

October 1, 2020 6:00 AM

GOLDEN, CO / ACCESSWIRE / October 1, 2020 / Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, announced its 3rd quarter, ended July 31st 2020, financial results of operations. Vitro Biopharma recorded 3rd quarter revenues of $132,066 vs $225,191 a decrease of 41% over the comparative quarter last year. Revenues were up slightly from the prior quarter which were $128,631. The decrease in revenue is directly attributed to the COVID 19...

Read more

Helix Biopharma Corp. Provides Polish Subsidiary Divestiture Update

September 30, 2020 5:00 PM

RICHMOND HILL, ON / ACCESSWIRE / September 30, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced an update on the progress regarding the non-binding term sheet the Company received and previous announced on June 26, 2020 to divest the...

Read more

DECN Signs Agreement With US-Based Laboratory as Testing Partner for Genviro! Saliva Swift Kit Testing for Additional FDA, EU CE Mark and Russian Federation Submissions

September 30, 2020 9:15 AM

FDA & CLIA certified laboratory will begin the testing of the Genviro! 10.5 Sec. Saliva Swift Kit, with full results expected to be reported to regulators in USA, EU and Russian Federation, and will also be included in the Genviro! Swift package inserts LOS ANGELES, CA / ACCESSWIRE / September 30, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) www.decisiondiagnostics.co, a leading manufacturer and worldwide distributor of...

Read more

Havn Life Sciences Inc. Reports Q1 Financial Statements

September 29, 2020 8:35 PM

VANCOUVER, BC / ACCESSWIRE / September 29, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), is pleased to announce Its financial results for the three month period ended July 31, 2020. Please note that all references to currency are in CDN dollars. First Quarter Results for three months ended July 31, 2020 - Financial highlights: The Company incurred net and comprehensive loss of...

Read more

Applied UV, Inc. Subsidiary, SteriLumen, Inc., Announces Filing of U.S. Patent Application for a System to Neutralize Pathogens on Physical Surfaces

September 29, 2020 8:30 AM

Sterilumen patent-pending UV Light sanitizing solution designed to be retrofitted to Bank ATMs to automatically disinfect surfaces on an ATM machine, including a keyboard, touchscreen, credit card reader between uses MOUNT VERNON, NY / ACCESSWIRE / September 29, 2020 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection prevention technology company that applies the power of narrow-range ultra...

Read more

EV Biologics To Perform Specialized Analysis of EV Biopharmaceuticals at Vanderbilt University

September 29, 2020 8:00 AM

CHEYENNE, WY / ACCESSWIRE / September 29, 2020 / EV Biologics, Inc. formerly Yulong Eco-Materials Limited (OTC PINK:YECO) today announced that it intends to utilize the advanced instrumentation and research staff at the Vanderbilt Institute of Nanoscale Science and Engineering (VINSE) and the Vanderbilt Center for Structural Biology (CSB) in the development of extracellular vesicle (EV)-based diagnostics and therapeutics. Founded in 1873,...

Read more

Lexaria Receives Conditional Ethics Board Approval for Pilot Human Study Using DehydraTECH Technology in Delivering Antiviral Drugs

September 29, 2020 6:25 AM

Company Raises Commitment to Antiviral Research with Launch of Rodent Antiviral Drug Delivery Study with Potential COVID-19 Applications KELOWNA, BC / ACCESSWIRE / September 29, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today provides an update on a previously announced antiviral research initiative and introduces a new research...

Read more

SCEMFIS Research Provides New Insights on Gray Seals; Suggests Alternatives to Current Management

September 28, 2020 4:45 PM

OCEAN SPRINGS, MS / ACCESSWIRE / September 28, 2020 / Decades of strict conservation and management have led to a rebound of gray seals in the North Atlantic. Now, research from the Science Center for Marine Fisheries (SCEMFIS) is providing new insights into this population, how local fisheries interact with them, and better options to manage them. The study, led by Drs. Doug DeMaster, Paula Moreno, Andre Punt, and John Brandon of the...

Read more